The Race Against a Rare Ebola: What the DRC's First Bundibugyo Antiviral Trial Means for Outbreak Medicine

There is a clinical trial about to begin in the Democratic Republic of Congo that most people in the pharmaceutical industry have not yet noticed. It does not involve a blockbuster drug, a billion-dollar acquisition, or a Phase 3 readout that will move a stock price. It involves a fast-moving outbreak of a rare Ebola variant, 1,094 confirmed cases, 277 deaths, and the first-ever attempt to test antivirals against the Bundibugyo ebolavirus in a randomized controlled trial. The WHO Director-General announced on June 24 that preparations are complete and the trial is expected to begin next week. What happens in the DRC over the coming weeks will matter far beyond the outbreak itself.

A Variant With No Approved Treatment

The Bundibugyo ebolavirus is one of six known species in the Ebolavirus genus. It was first identified in Uganda in 2007 and caused a second outbreak there in 2012. It is distinct from the Zaire ebolavirus responsible for the devastating 2014 to 2016 West African epidemic and the 2018 to 2020 DRC outbreak, during which the landmark PALM trial identified two effective antibody treatments. Those treatments, Inmazeb and Ebanga, were developed and approved specifically for Zaire ebolavirus. They do not cover Bundibugyo. When the current DRC outbreak was confirmed on May 15, 2026, there were no licensed therapeutics and no approved vaccines for the strain causing it. That remains true today.

The outbreak has grown rapidly. As of June 24, there are 1,094 confirmed cases and 277 deaths across the DRC. The virus has crossed borders: Uganda has reported 20 confirmed cases and two deaths, all linked to the DRC outbreak. On June 24, France reported that a health worker with the NGO ALIMA who returned after caring for Ebola patients in the DRC tested positive, a reminder that in a connected world, a contained outbreak is never truly contained. Almost 80 health workers have been infected in the DRC alone.

The Trial and What It Is Testing

The WHO-coordinated trial, known as PARTNERS, will evaluate two candidate therapeutics: MBP134, an experimental antibody cocktail developed by Mapp Biopharmaceutical, and remdesivir, the broad-spectrum antiviral marketed by Gilead Sciences as Veklury. Participants will be randomized to receive MBP134 alone, remdesivir alone, both drugs in combination, or neither, with all groups receiving supportive care. The trial is being conducted by a consortium that includes the DRC's National Institute for Biomedical Research, the Alliance for International Medical Action (ALIMA), Oxford University, and the WHO. The United States government and Gilead Sciences are donating doses for the trial.

The scientific rationale for each candidate is distinct. MBP134 is a combination of two monoclonal antibodies isolated from a survivor of the 2013 West African Ebola outbreak. In preclinical studies, the antibody cocktail protected ferrets and cynomolgus monkeys against infection with multiple Ebola species, including Bundibugyo. Virologist Thomas Geisbert of the University of Texas Medical Branch has described it as having "by far the strongest preclinical data for any of the treatments or therapies" being considered for this outbreak. Remdesivir's case is more nuanced. It was one of two drugs that failed to show benefit in the 2019 PALM trial against Zaire ebolavirus, but in vitro data show it is substantially more potent against Bundibugyo than against the Zaire strain. The biology of the target matters, and the biology here is different.

What the Field Has Learned Since 2015

The decision to launch a randomized controlled trial in the middle of an active outbreak, rather than simply deploying experimental drugs on compassionate use grounds, reflects a decade of hard-won lessons about how to generate evidence under pressure. In 2015, during the West African epidemic, clinical trials were slow to launch, poorly controlled, and often concluded after the outbreak had already peaked. The RAPIDE trial in Sierra Leone tested a single drug with no control group, and by the time results were available, the window for action had closed. The researchers who ran those trials spent years afterward redesigning their approach.

The PALM trial in 2019 demonstrated what a well-designed outbreak trial could achieve. By randomizing patients across four treatment arms and using a pre-specified adaptive design, investigators were able to identify two effective treatments and discontinue two ineffective ones within a single outbreak. The PARTNERS protocol being activated now draws directly on that experience, incorporating lessons from PALM and from the Oxford-led Recovery trial that transformed COVID-19 treatment by testing multiple interventions simultaneously with a streamlined data collection approach. The ethics board in the DRC has already approved the protocol. The infrastructure is in place. The trial is ready to begin.

The Equity Question That Will Not Go Away

The scientific progress embedded in this trial sits alongside a question that the field has not adequately answered. MBP134 was developed using antibodies isolated from a survivor of the West African Ebola outbreak, a person from a low-income country who survived a devastating disease and whose immune response became the foundation for a potential treatment. The drug's development has been funded substantially by the United States government, which owns the existing doses and has built the stockpile with the aim of protecting Americans in the event of a domestic Ebola exposure. The doses being donated for the DRC trial represent a meaningful gesture, but the broader question of who will have access to MBP134 if it proves effective, and at what cost, and under what conditions, remains unresolved.

Craig Spencer, a public health expert at Brown University and an Ebola survivor himself, has put the issue plainly: it is a moral failure to develop a drug using the biology of outbreak survivors in low-income countries, test its efficacy in those same countries because that is where outbreaks occur, and then stockpile the results for use in wealthy nations. That critique does not diminish the scientific value of the trial or the genuine commitment of the researchers running it. But it is a structural problem that the pharmaceutical industry and its government partners have not solved, and the DRC outbreak is making it visible again.

What the Outcome Will Mean

If MBP134 or remdesivir demonstrates efficacy against Bundibugyo ebolavirus in this trial, the implications extend well beyond the current outbreak. It would establish a treatment precedent for a strain that has caused three known outbreaks and could cause more. It would validate the PARTNERS adaptive trial design as a replicable model for future filovirus outbreaks, including Marburg, Sudan ebolavirus, and other variants for which no approved treatments exist. And it would generate the kind of randomized evidence that regulatory agencies require before granting approval, potentially creating a pathway to licensure that compassionate use alone cannot provide.

The harder challenge is the one that precedes efficacy: getting patients to enroll early, when viral loads are low enough for antivirals to work. In the DRC, where trust in the health system has been eroded by years of conflict and a history of outbreak responses that felt extractive rather than supportive, convincing people to enter a treatment center and agree to randomization is not a scientific problem. It is a social and political one. The researchers running PARTNERS understand this. The communities they are working with understand it too. Whether the trial can generate the evidence it needs before the outbreak fades or the logistics collapse is the question that will determine whether the field advances or waits for the next outbreak to try again.